Singh R, Creegan TP, Jacob L, Zhang JG. Development of UGT1A7 and UGT1A8 inhibition assays using recombinant enzymes as a test system. Poster presentation at the 22nd North American ISSX Meeting 2018, Montreal, Canada.
Stresser DM, Perloff ES, Mason AK et al. Selective time- and NADPH-dependent inhibition of human CYP2E1 by clomethiazole. Drug Metab Dispos. 2016;44(8):1424–1430.
Ritu Singh, Ph.D.
Ritu Singh is a group leader of the analytical chemistry/ADME team within the Center for the Development of Therapeutics (CDoT) at the Broad Institute of MIT and Harvard. Her group provides analytical and ADME (absorption, distribution, metabolism, excretion) testing capabilities to support discovery and development of small molecules in multiple therapeutic projects. She has a wide range of expertise in the areas of drug metabolism, metabolite identification, drug-drug interaction, transporters, and bio-analysis using liquid chromatography-mass spectrometry.
Prior to joining the Broad Institute in September 2018, Singh worked as a staff scientist and study director at Corning Life Sciences in Woburn, Massachusetts. She had previously worked in industry at Synta Pharmaceuticals, Cyprotex, Merial, and Merck.
Singh holds a Ph.D. from Rutgers University, an M.Pharm. from Bombay University, Mumbai, India, and a B.Pharm. from Shreemati Nathibai Damodar Thackersey Women’s University, Mumbai, India.
Contact Ritu Singh via email at email@example.com.